Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Australian Household Spending Dips in December as RBA Tightens Policy 
Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Asian Markets Surge as Japan Election, Fed Rate Cut Bets, and Tech Rally Lift Global Sentiment 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
